NeOnc Technologies Holdings, Inc., a clinical stage biopharmaceutical company, has received authorization by the U.S. Food and Drug Administration (FDA) for the Phase 1/2 clinical study of NEO212, the Company’s drug conjugate therapeutic under development. NEO212 is designed to more efficiently deliver a DNA alkylating agent to the brain for treatment of primary brain tumors and for brain metastases that…

March 6, 2023|Anova|News, Press ReleaseMarch 6, 2023Category: News, Press Release Anova Enterprises, a clinical research organization, to prepare FDA Fast Track and Rare Pediatric Designation application for NEO100® for Pediatric High-Grade Gliomas (pHGGS) brain tumors. AnovaOS™ platform to support efficient patient identification and enrolment. Program designed to build upon early success of NEO100 with IDH1 mutated brain tumors (high-grade gliomas) in adult patients.…

The objective of the ‘AnovaOS™ Network Powered Patient Registry Study’ is to globally capture clinically meaningful, real-world data on the diagnosis, nature, course of infection, treatment(s) and outcomes in patients with complex and rare disease.